Context Therapeutics advancing CT-202 into clinic in Australia

Context Therapeutics Inc. is advancing CT-202 into a first-in-human trial in Australia following Human Research Ethics Committee (HREC) approval and clinical trial notification acknowledgement by Australia’s Therapeutic Goods Administration (TGA).